

# Lipoprotein lipase deficiency: heterozygotes match homozygotes in severity

Dominika Szczęśniak<sup>1</sup>, Małgorzata Bednarska-Makaruk<sup>1</sup>, Olga Drgas<sup>2</sup>, Karolina Kowalczyk<sup>2</sup>, Magdalena M. Kacprzak<sup>2</sup>, Paweł Aleksandrowicz<sup>3</sup>, Lidia Kotuła<sup>4</sup>, Magdalena Mroczek<sup>5\*</sup>

<sup>1</sup>Department of Genetics, Institute Psychiatry and Neurology, Warsaw, Poland

<sup>2</sup>MedGen Medical Center, Warsaw, Poland

<sup>3</sup>Department of Dental Surgery, Medical University of Warsaw, Poland

<sup>4</sup>Department of Genetics, Medical University of Lublin, Lublin, Poland

<sup>5</sup>Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland

\*Corresponding author:

Magdalena Mroczek  
Department of Neurology  
University Hospital Basel  
University of Basel  
Basel, Switzerland  
E-mail: m.mroczek888@gmail.com

Submitted: 31 August 2024; Accepted: 15 February 2025

Online publication: 25 June 2025

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/201448>

Copyright © 2025 Termedia & Banach

## Abstract

**Introduction:** Biallelic pathogenic variants in the *LPL* gene are associated with familial lipoprotein lipase (LPL) deficiency. Homozygotes exhibit very severe hypertriglyceridemia (HTG) already in childhood, with phenotypic features such as pancreatitis, abdominal pain and xanthomata. Recent studies showed that HTG levels varied greatly between monoallelic *LPL* pathogenic/likely pathogenic variant carriers. The aim of our study was to investigate whether heterozygotes for pathogenic variants in the *LPL* gene in the Polish population may have clinical symptoms and, if so, to what extent.

**Material and methods:** Genetic data were derived from a Polish cohort of 5623 whole exome sequenced patients. In 52 cases the indication for WES genetic testing was “hypertriglyceridemia” and for 5571 there was another clinical indication, mainly autism spectrum disorder, dysmorphia and neurodegenerative diseases.

**Results:** We present 22 heterozygous and 2 homozygous/compound heterozygous individuals for the pathogenic/likely pathogenic *LPL* variant and describe HTG levels, phenotypic manifestations and age of onset in the context of molecular findings where available. We report for the first time heterozygous *LPL* individuals with very severe HTG (TG  $\geq$  22.6 mmol/l;  $>$  2000 mg/dl) and additional symptoms such as pancreatitis and recurrent abdominal pain.

**Conclusions:** We argue that although the individuals carrying the single *LPL* pathogenic/likely pathogenic variant display the whole disease spectrum, the severe phenotype of heterozygotes with dominantly inherited *LPL*-related HTG may also exist.

**Key words:** lipoprotein lipase, hypertriglyceridemia, hypertriglyceridemia, co-dominance, familial chylomicronemia syndrome, autosomal dominant.

## Introduction

Hypertriglyceridemia (HTG) is the most common lipid disorder, affecting approximately 10% of the world's population [1, 2]. The diagnosis of HTG depends on the fasting triglyceride levels. Based on the Endocrine Society Clinical Practice Guideline, HTG is classified as mild (tri-

glycerides (TG) 1.7–2.2 mmol/l; 150–199 mg/dl), moderate (TG 2.3–11.2 mmol/l; 200–999 mg/dl), severe (TG 11.3–22.5 mmol/l; 1000–1999 mg/dl), and very severe (TG  $\geq$  22.6 mmol/l; > 2000 mg/dl) [1, 2]. Familial non-syndromic HTG is caused nearly exclusively by biallelic defects of the following five major genes: *LPL*, *APOC2*, *APOA5*, *LMF1*, and *GPIHBP1*. Familial LPL deficiency is the most common form of familial hypertriglyceridemia and accounts for nearly 95% of all cases [3–7].

Biallelic pathogenic variants in the *LPL* gene are associated with familial lipoprotein lipase (LPL) deficiency (MIM #238600) [8], a disease manifesting with recurrent pancreatitis, abdominal pain, cutaneous xanthomata, and hepatosplenomegaly. At the molecular level, biallelic pathogenic variants in the *LPL* gene impair clearance from the chylomicrons to the plasma. The inheritance pattern of the disease is in general autosomal recessive. Heterozygotes are mostly asymptomatic but may have mild to moderate hypertriglyceridemia and may develop atherosclerosis at a younger age. The inheritance pattern of the familial lipoprotein lipase deficiency is also sometimes described as a codominant inheritance mode, where carriers of one allele of the recessively inherited gene exhibit only mild, often nonspecific symptoms and usually a late disease onset, whereas those homozygous for the pathogenic *LPL* variant present with a full disease phenotype [9]. In contrast, some diseases show both recessive and dominant inheritance, such as myotonia congenita (Thomsen myotonia with *CLCN1* pathogenic variants, dominant inheritance; MIM #160800 and Becker myotonia with *CLCN1* pathogenic variants, recessive inheritance, MIM #255700) [10] or calpainopathy (traditional recessive inheritance MIM #253600 and recently described dominant inheritance; MIM #618129) [11].

Since the beginning, the carrier status of the pathogenic/likely pathogenic *LPL* variants has been widely discussed. In one of the first studies investigating large pedigrees with heterozygous carriers, the LPL level, although decreased by about 50%, did not make it possible to differentiate between carriers and non-carriers with similar phenotypes and the same lipid levels occurring in both groups [12]. Carriers presented a pathogenic plasma lipid profile and lipid changes including increased TG, very-low-density lipoprotein (VLDL), and apolipoprotein B (apoB), and decreased low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Interestingly, these differences have been mainly observed only in probands older than 40 years, suggesting a contributory role of secondary and environmental factors, such as obesity and insulin resistance. Available studies have not been conclusive regarding the role of the pathogenic variants associated with monoallelic

hypertriglyceridemia and the intermediate phenotype [13, 14].

Some studies have reported that heterozygous carriers may present a range of HTG levels rather than a binary affected/non-affected status. In a cohort of 15 *LPL* pathogenic heterozygotes, the HTG level varied greatly, and 14.8%, 67.0%, and 18.2% were in the normal, mild-to-moderate, and severe HTG ranges, respectively, in the 1.5-year longitudinal studies [13]. In our group of Polish patients, we confirm not only the range of phenotypes but also a near-to-biallelic phenotype in heterozygotes and their parents, suggesting a dominant inheritance pattern.

## Material and methods

Whole exome sequencing (WES) was performed on 5623 Polish individuals (as of 23.05.2024). In 52 cases the indication for WES genetic testing was “hypertriglyceridemia” and for 5571 there was another clinical indication, mainly autism spectrum disorder, dysmorphia and neurodegenerative diseases. Technical sequencing was performed by CeGaT (Tübingen, Germany). Bioinformatic analysis and scientific and diagnostic interpretation of variants were performed by MEDGEN laboratory (Warsaw, Poland). The genomic DNA of patients was extracted from a whole blood sample using Prepito. The sequencing exome library was prepared according to Twist Exome Enrichment (Twist Bioscience). The enriched DNA libraries were sequenced by the Illumina NovaSeq 6000 instrument, 2 x 100 bp.

Raw sequencing reads were mapped to the human reference genome GRCh37 and GRCh38 assembly using BWA MEM (bwa-mem2.avx2 mem 0.7.17-r1188) [15]. Duplicates were removed using biobambam2 version 2.0.183 [16]. Variants were called using HaplotypeCaller (GATK v4.2.6.1 [17, 18]) and FreeBayes v1.3.2 [19], and named using Variant Effect Predictor (VEP109) [20]. The variants were classified according to ACMG recommendations [21]. The presence of the variant in control populations was checked in 1000 Genomes [22] and gnomAD (v4) (Broad Institute) databases [23]. The in silico splicing analysis was performed using algorithms embedded in Alamut Visual Plus software (Sophia Genetics), i.e. SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer and SpliceAI [24]. The presence of the detected pathogenic/likely variants was confirmed by Sanger sequencing. The XHMMv1.0 algorithm and in-house scripts were used to search for small, rare, hemizygous and homozygous copy number variant (CNVs).

All exomes were searched first for variants in the *LPL* gene reported in the ClinVar database as “pathogenic/potentially pathogenic” regardless of

reported clinical manifestations. Then, our entire WES database was searched for rare nonsense variants, frameshifts and canonical splicing, and large deletions and duplications not reported in the ClinVar database. For patients included in our study, pathogenic rare variants were only found in *LPL* and none of the other canonical familial chylomicronemia syndrome (FCS) genes (i.e. *APOC2*, *APOA5*, *GPIHBP1* and *LMF1*) [25].

## Results

### Genetic findings in the Polish cohort

The tested individuals were 1–76 years old (Table I). In the WES analysis of individuals with “hypertriglyceridemia” as an indication for testing, there was a pathogenic/likely pathogenic *LPL* variant present in 23% (12 out of 52). In the WES analysis of individuals with “other (not hypertriglyceridemia)” as an indication for testing, there was a pathogenic/likely pathogenic variant in 0.18% (10/5571) ( $p < 0.05$ ).

In 17 individuals the variant(s) in the *LPL* gene have been reported as pathogenic in ClinVar and in 7 cases the variants have not been reported as pathogenic in ClinVar, but fulfilled the pathogenicity criteria according to the ACMG classification (Table I, Figure 1). One patient was homozygous and one compound heterozygous for the pathogenic *LPL* variants. Interestingly, in 2 cases there was a CNV in the *LPL* gene causing duplication of the whole exome 6 and predicted to be pathogenic according to ACMG criteria. Thirteen individuals were diagnosed with HTG, whereas 11 were not, despite carrying a pathogenic variant.

In the group of patients with a known pathogenic variant, 15 were heterozygous, 1 was homozygous, and 1 was a compound heterozygous.


### Phenotype analysis

In 11 cases the heterozygotes for the pathogenic *LPL* variant did not present elevated TG levels, whereas in 11 cases they did. We then investigated common *LPL* variants: *LPL* p.Trp113Arg

**Table I.** Variants, zygoty, TG levels, and approximate age at molecular diagnosis in patients with pathogenic *LPL* variant

No.	Variant	Allelicity	Hypertriglyceridemia	Approximate age in years at genetic testing	ClinVar (as for 14.05.2024)
1	p.Ile221Thr	het	No	2	Yes
2	p.Trp113Arg	het	No	9	Yes
3	p.Trp113Arg	het	No	9	Yes
4	p.Gly215Glu	het	No	6	Yes
5	p.Gly215Glu	het	No	18	Yes
6	p.Gly215Glu	het	No	11	Yes
7	p.Ile252Thr	het	No	7	Yes
8	p.Arg270Cys	het	No	14	Yes
9	p.Trp113Arg	het	No	1	Yes
10	p.Arg219Ter	het	No	5	No
11	p.Ser17AspfsTer22	het	No	59	No
12	p.Arg270His	het	1000 mg/dl	10	Yes
13	p.Arg333His	het	800 mg/dl	2	Yes
14	Trp113Arg	hom	2000 mg/dl	11	Yes
15	p.Ile221Thr	het	1000 mg/dl	2	Yes
16	p.Trp113Arg/ Arg197Leu	comp het	2500 mg/dl	38	Yes
17	p.Trp113Arg	het	800 mg/dl	76	Yes
18	p.Asp183Asn	het	500 mg/dl	15	Yes
19	p.Gly215Glu	het	600 mg/dl	1	Yes
20	p.Gln240Ter	het	3500 mg/dl	50	No
21	c.1018+1G>A	het	800 mg/dl	3	No
22	Duplication ex 6	het	728 mg/dl	14	No
23	Duplication ex 6	het	2000 md/dl	45	No
24	p.Arg270Ser	het	3000 mg/dl	52	No

Heterozygotes with a pathogenic/likely pathogenic variant in the LPL gene



**Figure 1.** Distribution of the pathogenic/likely pathogenic (according to the ACMG criteria) ClinVar and non-ClinVar variants in the heterozygotes with and without HTG

**Table II.** TG levels divided by variant

Variant	TG normal	HTG
For all pathogenic variants	11	11
p.Gly215Glu	3	1
p.Trp113Arg	3	2

and *LPL* p.Gly215Glu. Two *LPL* p.Trp113Arg carriers had HTG (age 11 and 76) and 3 normal HTG levels (age 9, 9, and 1 year). One *LPL* p.Gly215Glu carrier showed HTG (age 1 year) and three normal TG levels (age 6, 11, and 18 years) (Table II).

Interestingly, not only HTG has been found in heterozygotes, but also 8 monoallelic patients had clinical symptoms, including non-specific symptoms such as abdominal pain and periodic nausea (Table III). Three out of 8 patients had at least 1 episode of acute pancreatitis in the history, while 3 had enlargement of the liver and/or spleen. None of these symptomatic patients drank alcohol. One patient had only moderately high triglyceride levels without additional symp-

**Table III.** Phenotypic features of individuals with HTG and heterozygous pathogenic *LPL* variants

No.	Year of birth	Sex	Variant	Exon according to MANE sequence	HTG max levels [mg/dl]	Family segregation	Type of variant	BMI	Concomitant disorders
1	6	Male	p.Ile221Thr	Exon 5	1000 mg/dl	NA	Missense	NA	NA
2	3	Female	c.1018+1G>A	Intron 6	800 mg/dl	Yes, mother with HTG	LoF	18.50	No
3	45	Female	dup. ex 6	Dup 6	2000 mg/dl	Yes, mother of case 4	LoF	22.00	Pancreatitis
4	14	Female	dup ex 6	Dup 6	728 mg/dl	Yes, mother (case 3) with HTG	LoF	19.50	No
5	45	Female	p.Gly215Glu	Exon 5	600 mg/dl	NA	Missense	NA	Recurrent abdominal pain
6	50	Male	p.Gln240Ter	Exon 5	3500 mg/dl	Nobody from the family inherited the variant	LoF	36.33	Asthma, coronary artery disease, pancreatitis (x3)
7	52	Female	p.Arg270Ser	Exon 6	> 3000 mg/dl	Nobody from the family inherited the variant	Missense	25.30	Pancreatitis (x1) Hypertension
8	76	Female	p.Trp113Arg	Exon 3	800 mg/dl	NA	Missense	14.00	Essential tremor, coronary artery disease, hypertension
9	2	Female	p.Arg333His	Exon 6	800 mg/dl	Yes, mother with HTG	Missense	NA	Recurrent abdominal pain
10	10	Male	p.Arg270His	Exon 6	1000 mg/dl	NA	Missense	NA	Autism, recurrent abdominal pain
11	15	Female	p.Asp183Asn	Exon 5	500 mg/dl	NA	Missense	27.00	Autism, recurrent abdominal pain

toms typical of *LPL* deficits. There was a correlation between the presence of the HTG and age in the group of heterozygous *LPL* individuals. The medium age in the heterozygotes with HTG was 24.5 years (2–76 years), whereas in the heterozygotes without HTG it was 12.8 years (1–59 years).

We identified 3 individuals with a heterozygous *LPL* pathogenic variant (according to the ACMG criteria) and very severe HTG (TG  $\geq$  22.6 mmol/l;  $>$ 2000 mg/dl) (Table I). In 2 cases the TG level exceeded 3000 mg/dl. All of the individuals presented with pancreatitis – a symptom related to HTG. One of the patients even suffered from 3 episodes of severe pancreatitis. One individual with severe/very severe HTG had a normal BMI, one was mildly overweight (BMI 25.3 kg/m<sup>2</sup>) and one was obese (BMI 36.3 kg/m<sup>2</sup>) (Table III). All these three individuals were older than 40 at the time of the genetic testing. Two variants were loss-of-function (LoF): one was a duplication of the whole exon 6, and one was classified as a missense. All variants were located in exons 5 and 6 of the *LPL* gene. None of the variants has been reported in ClinVar, and all variants were classified as pathogenic according to the ACMG classification.

Segregation analysis was performed in all three cases. In 2 cases, nobody from the family inherited the variants. In patient 3, a daughter (born in 2009) affected with the same deletion showed TG of more than 700 mg/dl in the 2nd decade of life already.

## Discussion

We described the phenotypic and molecular spectrum of a large cohort of homo- and heterozygous individuals for pathogenic variants in the *LPL* gene. We found that individuals with a heterozygous *LPL* variant present the whole range of phenotypes, from being asymptomatic to displaying the severe, fully developed phenotype with very severe HTG and clinical symptoms. We cannot exclude that the development of the phenotype is influenced by factors such as sex, age, environment, and comorbidities.

The heterozygotes with HTG were older than those without HTG; however, there was no age threshold for symptoms of heterozygous individuals with very severe HTG presenting already at the age of 2. For example, the variant *LPL* p.Gly215Glu was reported in a young child (2 years old) with severe HTG, whereas older children with the same variant were asymptomatic (Table I) – raising a question about the influence of environmental exposure. This is in contrast to the study by Perera *et al.* [13], where only one individual out of 15 had HTG below the age of 40. There was no correlation between the type of variant (LoF or missense) and disease severity/presence of HTG

in the laboratory testing. This is in opposition to some studies that suggested a more severe phenotype in the LoF variants than in missense variants in the *LPL* gene [13, 26, 27]. Two patients with very severe HTG presented with LoF variants. In one case, we report a duplication of exon 6. Heterozygous deletions in the *LPL* gene have been already associated with severe, but not very severe HTG [28, 29]. In a few patients in the literature, duplications disrupting exon 6 have been associated with very severe HTG, but without any symptoms related to it, such as pancreatitis; however, no genotype-phenotype correlation could be established [29].

We confirm that the heterozygous *LPL* carriers may present with the full range of phenotypes. This is in accordance with the recent approach not to classify the disease as dominant and recessive but rather as a heterozygosity spectrum. Additionally, we found that the *LPL* heterozygotes may exhibit very severe HTG in laboratory testing and show clinical manifestations and dominant variant inheritance patterns. The inheritance pattern of the *LPL* gene is described either as recessive or codominant, meaning that two pathogenic variants determine a more severe phenotype while heterozygotes for the pathogenic variants in the *LPL* gene have an intermediate phenotype. We argue that *LPL* could also follow a dominant inheritance pattern with affected parents passing the variant related to the phenotype to their offspring. It should not be forgotten that the development of the phenotype is certainly influenced by factors such as age, sex, and comorbidities (Table III).

For the first time, we report the frequency of the heterozygous pathogenic/likely pathogenic *LPL* variants in the Polish population, estimated at 1 : 1000 individuals. An important fact is that the majority of samples for the WES examinations derive from the MEDGEN laboratory with the indication for intellectual disability, autism, dysmorphia, and neurodegenerative diseases. Because mainly these indications are the focus of referring physicians, they often forget to enter a symptom such as ‘hypertriglyceridemia’, considering it less clinically relevant. It is therefore possible that there are indeed more of these symptomatic *LPL* heterozygotes, as this group is not fully characterized clinically. It is important to remember that because of the indications for testing, including HTG and hypercholesterolemia, that there is an overrepresentation of HTG in our cohort, so it is not representative for the whole Polish population. In the future, it would be advisable to study a random population group.

Our study has several limitations. Some of them are related to the technical limitations of the meth-



odology. Whole exome sequencing can detect only coding sequences, which leaves a possibility that there is a structural or a splice site variant that has been omitted, especially in severely affected heterozygous individuals. Another technical limitation is that the deletion of exon 6 has not been confirmed by the second molecular method. Secondly, we have only limited phenotypic data. We do not have exact lipid levels for individuals without pathogenic *LPL* variants identified, which may be a source of bias. Also, we do not have full data on the environmental and secondary factors, influencing *LPL* levels. Especially information on the BMI is missing in several cases, which may be a source of bias. We do not have a longitudinal follow-up, so we cannot reliably describe the age of onset of the HTG and age when HTG develops, which means we cannot rule out that the asymptomatic heterozygotes will become symptomatic at a later point of life. Additionally, we did not investigate a polygenic risk score in the heterozygotes. Polygenic accumulation of genetic risk is associated with a mild [30], but also severe HTG disease form [31]. Common variants account for most of the mild HTG cases [32], but also for around 46% of cases of the severe disease form [30].

In conclusion, we argue that although the individuals carrying the single *LPL* pathogenic/likely pathogenic variant display the whole disease spectrum, the severe phenotype of heterozygotes with dominantly inherited *LPL*-related HTG may also exist. There was no clear association between the type of variant and the onset of the disease. Phenotypic and demographic characterization of further heterozygotes should help to better understand the background of the symptomatic spectrum.

### Funding

No external funding.

### Ethical approval

Not applicable.

### Conflict of interest

The authors declare no conflict of interest.

### References

1. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. *Eur Heart J* 2020; 41: 99-109.
2. Simha V. Management of hypertriglyceridemia. *BMJ* 2020; 371: m3109.
3. Al-Waili K, Al-Rasadi K, Al-Bulushi M, et al. The genetic spectrum of familial hypertriglyceridemia in Oman. *Front Genet* 2022; 13: 886182.
4. Shah AS, Wilson DP. Genetic Disorders Causing Hypertriglyceridemia in Children and Adolescents. [Updated 2023 Feb 22]. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds.). *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK395571/>
5. Futema M, Ramaswami U, Tichy L, et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. *Atherosclerosis* 2021; 319: 108-17.
6. Di Taranto MD, Giacobbe C, Buonaiuto A, et al. A real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia. *J Clin Med* 2020; 9: 219.
7. Bañares VG, Corral P, Medeiros AM, et al. Preliminary spectrum of genetic variants in familial hypercholesterolemia in Argentina. *J Clin Lipidol* 2017; 11: 524-31.
8. Burnett JR, Hooper AJ, Hegele RA. Familial lipoprotein lipase deficiency. 1999 Oct 12 [Updated 2017 Jun 22]. In: Adam MP, Feldman J, Mirzazadeh GM, et al. (eds.). *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1308/>
9. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. *Clin Biochem Rev* 2008; 29: 11-26.
10. Dunø M, Colding-Jørgensen E, Grønnet M, et al. Difference in allelic expression of the *CLCN1* gene and the possible influence on the myotonia congenita phenotype. *Eur J Hum Genet* 2004; 12: 738-43.
11. Angelini C. Calpainopathy. In: *GeneReviews*®. Adam MP, Feldman J, Mirzazadeh GM, et al. (eds.). Seattle (WA): University of Washington, Seattle; May 10, 2005.
12. Wilson DE, Emi M, Iverius PH, et al. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. *J Clin Invest* 1990; 86: 735-50.
13. Perera SD, Wang J, McIntyre AD, Dron JS, Hegele RA. The longitudinal triglyceride phenotype in heterozygotes with *LPL* pathogenic variants. *J Clin Lipidol* 2023; 17: 87-93.
14. Marusic T, Sustar U, Sadiq F, et al. Genetic and clinical characteristics of patients with homozygous and compound heterozygous familial hypercholesterolemia from three different populations: case series. *Front Genet* 2020; 11: 572176.
15. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; 25: 1754-60.
16. Tischler G, Leonard S. biobambam: tools for read pair collation based algorithms on BAM files. *Source Code for Biology and Medicine*. 2014; 9: 13. <https://gitlab.com/german.tischler/biobambam2>
17. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; 20: 1297-303.
18. Poplin R, Ruano-Rubio V, DePristo MA, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. *bioRxiv* 201178; doi: <https://doi.org/10.1101/201178>.
19. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. 2012. *arXiv* <https://doi.org/10.48550/arXiv.1207.3907>.
20. McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. *Genome Biol* 2016; 17: 122.
21. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus

- sus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; 17: 405-24.
22. 1000 Genomes Project Consortium; Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. *Nature* 2015; 526: 68-74.
  23. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature* 2024; 625: 92-100.
  24. Jaganathan K, Kyriazopoulou Panagiotopoulou S, et al. Predicting splicing from primary sequence with deep learning. *Cell* 2019; 176: 535-48.e24.
  25. Regmi M, Rehman A. Familial Hyperchylomicronemia Syndrome. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551655/>.
  26. Nordestgaard BG, Abildgaard S, Wittrup HH, et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. *Circulation* 1997; 96: 1737-44.
  27. Zhang G, Hu Y, Yang Q, et al. Frameshift coding sequence variants in the LPL gene: identification of two novel events and exploration of the genotype-phenotype relationship for variants reported to date. *Lipids Health Dis* 2023; 22: 128.
  28. Dron JS, Wang J, McIntyre AD, et al. Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia. *J Lipid Res* 2019; 60: 1953-8.
  29. Langlois S, Deeb S, Brunzell JD, Kastelein JJ, Hayden MR. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. *Proc Natl Acad Sci USA* 1989; 86: 948-52.
  30. Dron JS, Wang J, McIntyre AD, Cao H, Hegele RA. The polygenic nature of mild-to-moderate hypertriglyceridemia. *J Clin Lipidol* 2020; 14: 28-34.
  31. Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. *J Clin Lipidol* 2019; 13: 80-8.
  32. Carrasquilla GD, Christiansen MR, Kilpeläinen TO. The genetic basis of hypertriglyceridemia. *Curr Atheroscler Rep* 2021; 23: 39.